The most common systemic side effects nausea, vomiting, diarrhea come from the medication itself, not from injection technique, and tend to be strongest in the first weeks or after a dose increase
This highlights the necessity of preserving or increasing MM during weight loss to limit metabolic slowdown, prevent plateaus, and reduce the risk of weight regain
The FDA is being cautious about allowing distribution of a compound without comprehensive safety data
Weekly injections: Compounded semaglutide
Semaglutide GLP-1 option commonly associated with Wegovy, Ozempic, and Rybelsus
Semaglutide also carries a boxed warning about thyroid C-cell tumors occurring in rodents (with unknown risk in humans)